This Biopharma Stock Has Surged Nearly 100% and One Fund Just Locked in Gains With a $10 Million Exit

Arcutis Biotherapeutics develops topical therapies for chronic skin conditions, with a portfolio targeting psoriasis and atopic dermatitis.On February 5, Tejara Capital reported selling out of Arcutis Biotherapeutics (ARQT 0.04%), unloading 520,503 shares in an estimated $9.81 million trade based on quarterly average pricing.What happenedAccording to a U.S. Securities and Exchange Commission (SEC) filing dated February 5, Tejara Capital reported selling its entire holding of 520,503 shares in Arcutis Biothe ...